Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects

Osterix is regulated by Erk1/2 during osteoblast differentiation

(2011) You Hee Choi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Osteoporosis: now and the future

(2011) Tilman D Rachner et al.   LANCET

The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts

(2010) Hichame Id Boufker et al.   BMC CANCER

Tumor–host cell interactions in the bone disease of myeloma

(2010) Jessica A. Fowler et al.   BONE

Advances in the understanding of myeloma bone disease and tumour growth

(2010) Shmuel Yaccoby   BRITISH JOURNAL OF HAEMATOLOGY

Transplantation of Mesenchymal Stem Cells Exerts a Greater Long-Term Effect than Bone Marrow Mononuclear Cells in a Chronic Myocardial Infarction Model in Rat

(2010) Manuel Mazo et al.   CELL TRANSPLANTATION

Novel Bone-Targeted Strategies in Oncology

(2010) S. Vallet et al.   CLINICAL CANCER RESEARCH

Bone Marrow Mesenchymal Stem Cells: Historical Overview and Concepts

(2010) Pierre Charbord   HUMAN GENE THERAPY

Bone marrow stromal cells (bone marrow-derived multipotent mesenchymal stromal cells) for bone tissue engineering: Basic science to clinical translation

(2010) Hideaki Kagami et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo

(2010) Kate Vandyke et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro

(2010) S Jönsson et al.   LEUKEMIA

Osteoblastogenesis and tumor growth in myeloma

(2010) Shmuel Yaccoby   LEUKEMIA & LYMPHOMA

Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts

(2010) Y-C Lee et al.   ONCOGENE

Concise Review: Insights from Normal Bone Remodeling and Stem Cell-Based Therapies for Bone Repair

(2010) Sundeep Khosla et al.   STEM CELLS

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network

(2009) E. Terpos et al.   ANNALS OF ONCOLOGY

Bortezomib induces osteoblast differentiation via Wnt-independent activation of  -catenin/TCF signaling

(2009) Y.-W. Qiang et al.   BLOOD

Dysregulation of bone remodeling by imatinib mesylate

(2009) K. Vandyke et al.   BLOOD

Multiple Myeloma Bone Marrow Niche

(2009) Grzegorz Basak et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease

(2009) Katia Todoerti et al.   EXPERIMENTAL HEMATOLOGY

Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors

(2009) M Garayoa et al.   LEUKEMIA

Osteoclast lineage and function

(2008) H. Kalervo Väänänen et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Validation of PDGFR  and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib

(2008) A. M. L. Coluccia et al.   BLOOD

Metabolism and Disposition of Dasatinib after Oral Administration to Humans

(2008) L. J. Christopher et al.   DRUG METABOLISM AND DISPOSITION

PDGF Receptor β Is a Potent Regulator of Mesenchymal Stromal Cell Function

(2008) Ayano Tokunaga et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor

(2008) N Brownlow et al.   LEUKEMIA

Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis

(2008) K Vandyke et al.   LEUKEMIA

Pathogenesis of myeloma bone disease

(2008) G D Roodman   LEUKEMIA

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY

RANK ligand as a therapeutic target for bone metastases and multiple myeloma

(2007) G. David Roodman et al.   CANCER TREATMENT REVIEWS